title: Antitumor effects of celecoxib in COX-2 expressing and non-expressing canine melanoma cell lines.
abstract: Cyclooxygenase-2 (COX-2) is a potential target for chemoprevention and cancer therapy. Celecoxib, a selective COX-2 inhibitor, inhibits cell growth of various types of human cancer including malignant melanoma. In dogs, oral malignant melanoma represents the most common oral tumor and is often a fatal disease. Therefore, there is a desperate need to develop additional therapeutic strategies. The purpose of this study was to investigate the anticancer effects of celecoxib on canine malignant melanoma cell lines that express varying levels of COX-2. Celecoxib induced a significant anti-proliferative effect in both LMeC and CMeC-1 cells. In the CMeC cells, treatment of 50 μM celecoxib caused an increase in cells in the G0/G1 and a decreased proportion of cells in G-2 phase. In the LMeC cells, 50 μM of celecoxib led to an increase in the percentage of cells in the sub-G1 phase and a significant activation of caspase-3 when compared to CMeC-1 cells. In conclusion, these results demonstrate that celecoxib exhibits antitumor effects on canine melanoma LMeC and CMeC-1 cells by induction of G1-S cell cycle arrest and apoptosis. Our data suggest that celecoxib might be effective as a chemotherapeutic agent against canine malignant melanoma.
authors.affiliation: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Chungnam National University, 99 Daehakro, Yuseoung gu, Daejon 305-764, Korea.
authors.forename: Kyoung-Won
authors.initials: KW
authors.lastname: Seo
authors.affiliation: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
authors.forename: Ye-Rin
authors.initials: YR
authors.lastname: Coh
authors.affiliation: Department of Surgical and Radiological Sciences, School of Veterinary Medicine, University of California Davis, Davis, CA 95616, USA.
authors.forename: Robert B
authors.initials: RB
authors.lastname: Rebhun
authors.affiliation: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
authors.forename: Jin-Ok
authors.initials: JO
authors.lastname: Ahn
authors.affiliation: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
authors.forename: Sei-Myung
authors.initials: SM
authors.lastname: Han
authors.affiliation: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea.
authors.forename: Hee-Woo
authors.initials: HW
authors.lastname: Lee
authors.affiliation: Department of Veterinary Internal Medicine, College of Veterinary Medicine, Seoul National University, 599 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea. Electronic address: hyyoun@snu.ac.kr.
authors.forename: Hwa-Young
authors.initials: HY
authors.lastname: Youn
mesh_terms: D000818:Animals; D015153:Blotting, Western / Q000662:veterinary; D000068579:Celecoxib; D059447:Cell Cycle Checkpoints / Q000502:physiology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D052246:Cyclooxygenase 2 Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism*; D004285:Dogs; D005434:Flow Cytometry / Q000662:veterinary; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000662:veterinary*; D009062:Mouth Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000662:veterinary*; D011720:Pyrazoles / Q000494:pharmacology* / Q000627:therapeutic use; D013449:Sulfonamides / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D051546:Cyclooxygenase 2; D000068579:Celecoxib
keywords: Antitumor effects; COX-2 inhibitors; Canine melanoma; Celecoxib